Paper evaluates whether inhibiting catechol-O-methyltransferase (COMT) affects plasma homocysteine concentrations in levodopa-treated Parkinson’s disease patients.

Findings are clinically actionable because reduced levodopa-induced homocysteine via COMT inhibition could lower vascular and potential neurotoxic risk and guide adjunct strategies (COMT inhibitor choice or B‑vitamin management) to improve long-term outcomes, though lack of an abstract limits…